Zongatinib (Zongatinib) launch time and patient purchase channel description

Zongertinib (trade name: Zongertinib) is a new type of targeted anti-tumor drug, mainly used for patients with advanced solid tumors with specific mutations or target-positive tumors. According to the latest information, the drug has been approved for marketing in China, providing domestic patients with a new treatment option. However, due to the relatively short time on the market, the availability of the drug in hospitals or pharmacies in various places is still limited, and some patients may need to go through designated hospitals or special drug supply channels to obtain it.

After being launched in China, Zongertinib usually needs to be purchased with a doctor's prescription. Patients can first inquire about the supply of the drug through large tertiary hospitals or cancer specialist centers. Some areas may not yet have an official in-hospital pharmacy system, so patients can learn about purchase channels from the hospital pharmacy department, clinical research department, or drug approval channels when seeing a doctor. At the same time, doctors will also formulate individualized medication plans based on the patient's condition, target test results, and treatment plan.

The price of the original Zongertinib drug marketed overseas is relatively high. It is understood that the cost of a single course of treatment or a single month of this drug in the U.S. market is approximately 20 more than 10,000 yuan, and there is currently no generic version to replace it. This means that overseas purchase costs are higher and generally only applies to patients who obtain drugs through international medical services, clinical trials or imported drug channels. When purchasing overseas, patients need to pay attention to issues such as drug transportation, storage, and customs declaration, and use them under the guidance of a doctor to ensure the efficacy and safety of the drug.

Generally speaking, as a newly launched targeted drug, zongatinib has limited access to domestic patients but is gradually improving. Patients can obtain drugs through regular hospitals, doctor's prescriptions and specially approved import channels. Although overseas purchase is feasible, it is expensive and the process is complicated. In the future, with the improvement of the domestic drug supply system and medical insurance coverage, the accessibility of zongatinib is expected to increase, providing more convenient medication routes and clinical options for targeted therapy patients.

Reference materials:https://www.drugs.com/